In vitro Models of Tumor Microenvironment for New Cancer Target and Drug Discovery, 11/17 – 11/19/2014, Hyatt Boston Harbor
Reporter: Aviva Lev-Ari, PhD, RN
On 7/21/2014 Cambridge Healthtech Institute Announced:
Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494, http://www.healthtech.com
FINAL AGENDA ANNOUNCEMENT: REGISTER BY AUGUST 22 & SAVE UP TO $400!
Traditional drug screening relies on monolayer cell culture, which is not always predictive of natural physiological state. This is especially problematic in cancer drug discovery, where simple cell cultures are not predictive of complex tumor microenvironment that consists of various cell types that interact in 3-dimensional structures. As the cost of drug development rises, there is increasing pressure for more predictive in vitro models for functional analysis and compound characterization. Cambridge Healthtech Institute’s Second Annual Physiologically-Relevant Cellular Tumor Models for Drug Discovery meeting will focus on the latest advances in 3D cellular tumor models and complex co-culture systems for functional analysis studies and compound screening/characterization.
KEYNOTE PRESENTATION:
An All-Human Microphysiologic Liver System for Carcinoma Metastasis
Alan H. Wells, M.D., D.M.Sc., Vice Chair and Thomas J. Gill III Professor, Pathology, University of Pittsburgh
ENGINEERING AND SCREENING TUMOR SPHEROID MODELS
New Tricks for Spheroids: Mimicking Stromal Interactions, Investigating Nanoparticle Drug Delivery, and Modeling Resection
Mark Grinstaff, Ph.D., Professor, Chemistry, Boston University
Functional Analysis of Therapeutic Antibodies and Antigens Using ex vivo Tumor Spheroids
Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health
TECHNOLOGY SHOWCASE: 3D CELLULAR MODELS FOR DRUG AND TARGET SCREENING
High-Throughput Compatible Co-Spheroid Model Analyzing Compound Effects on Both Tumor and Stroma Cells
Jan E. Ehlert, Ph.D., Head, Cellular Drug Discovery, ProQinase GmbH
Sponsored by: ProQinase GmbH
Additional sponsorship opportunities available. Contact Ilana Quigley at iquigley@healthtech.com.HIGH-CONTENT ANALYSIS OF TUMOR SPHEROID MODELS
Drug Discovery and Development of Novel Anticancer Agents: Applications of Novel 3D Multicellular Tumor Spheroid Models
Daniel V. LaBarbera, Ph.D., Assistant Professor, Drug Discovery and Medicinal Chemistry, The Skaggs School of Pharmacy and Pharmaceutical Sciences, The University of Colorado
Novel Stromal Targets that Support Tumor Spheroid Formation
Shane R. Horman, Ph.D., Research Investigator, Advanced Assay Group, Genomics Institute of the Novartis Research Foundation
Developing Biodynamic Screening Assays for 3D Live-Tissue Models
David Nolte, Ph.D., Professor, Physics, Purdue University; President, Animated Dynamics, Inc.
ENGINEERING COMPLEX 3D MODELS OF TUMOR MICROENVIRONMENT FOR DRUG SCREENING AND FUNCTIONAL ANALYSIS
Targeted Electric Field Therapy Development in 3D Models of the Heterogeneous Glioma Microenvironment
Scott S. Verbridge, Ph.D., Assistant Professor, School of Biomedical Engineering and Sciences, Virginia Tech – Wake Forest University
Targeting Physical and Stromal Determinants of Tumor Heterogeneity in Bioengineered 3D Models
Imran Rizvi, Ph.D., Instructor, Medicine and Dermatology, Harvard Medical School; Associate Bioengineer, Brigham and Women’s Hospital; Assistant, Biomedical Engineering, Wellman Center for Photomedicine, Massachusetts General Hospital
Hydrogel Co-Culture Systems for Growing Patient-Derived Xenografts: Use in Selective Drug Screening
Mary C. Farach-Carson, Ph.D., Ralph and Dorothy Looney Professor, Biochemistry and Cell Biology; Scientific Director, BioScience Research Collaborative, Rice University
Human Stroma-Derived Extracellular Matrices: 3D ECM Physiological Systems
Edna Cukierman, Ph.D., Associate Professor, Cancer Biology, Fox Chase Cancer Center
ENGINEERING IN VITRO MODELS OF CANCER METASTASIS
Microfluidic Models with Microvascular Networks to Study Metastatic Disease
Roger D. Kamm, Ph.D., Cecil and Ida Green Distinguished Professor, Biological and Mechanical Engineering, MIT
Monitoring Extravascular Migratory Metastasis of Angiotropic Cancer Cells Using a 3D in vitro Co-Culture System
Claire Lugassy, M.D., Research Associate Professor, Pathology and Lab Medicine, UCLA School of Medicine; Member, Jonsson Comprehensive Cancer Center
Using Block Cell Printing to Develop Single Cell Arrays for Drug Screening
Lidong Qin, Ph.D., Associate Member, Nanomedicine, Methodist Hospital Research Institute; Assistant Professor, Cell and Developmental Biology, Weill Cornell Medical College
————————————————————————
RECOMMENDED DINNER SHORT COURSES*
Stem Cell Models for Drug Discovery
Monday Evening, November 17 | 6:30-9:30 pm
Instructors:
Anne G. Bang, Ph.D., Director, Cell Biology, Prebys Center, Sanford-Burnham Medical Research Institute
Pamela J. Hornby, Ph.D., Senior Scientific Director and Research Fellow, Cardiovascular and Metabolic Disease, Translational Models, Janssen Pharmaceutical Companies of Johnson & Johnson
Wei Zheng, Ph.D., Group Leader, National Center for Advancing Translational Sciences, National Institutes of Health
Expert ThinkTank: How to Meet the Need for Physiologically-Relevant Assays?
Tuesday Evening, November 18 | 6:00-9:00 pm
Moderator:
Lisa Minor, Ph.D., President, In Vitro Strategies, LLC
Panelists:
Beverley Isherwood, Ph.D., Team Leader, AstraZeneca R&D
Michael Jackson, Ph.D., Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute (tentative)
Jean-Louis Klein, Ph.D., Principal Scientist, Target and Pathway Validation, Platform Technology and Science, GlaxoSmithKline
Caroline Shamu, Ph.D., Director, ICCB-Longwood Screening Facility and Assistant Professor, Harvard Medical School
D. Lansing Taylor, Ph.D., Director, University of Pittsburgh Drug Discovery Institute and Allegheny Foundation; Professor, Computational and Systems Biology, University of Pittsburgh
Scott S. Verbridge, Ph.D., Assistant Professor, School of Biomedical Engineering and Sciences, Virginia Tech – Wake Forest University
Leave a Reply